Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Handa PharmaceuticalsROCO:6620 +3.65%76 3-Year ROIIC % is 49.11 as of Dec. 2025, which is 5% below its 10-year median of 51.77. GuruFocus rates ROCO:6620 with a GF Score™ of 76/100 and a GF Value™ of NT$153.49 (Significantly Undervalued). Among 944 Drug Manufacturers companies, Handa Pharmaceuticals ranks better than 83.37% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Handa Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 49.11%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Handa Pharmaceuticals's 3-Year ROIIC % or its related term are showing as below:
ROCO:6620's 3-Year ROIIC % is ranked better than 83.37% of 944
companies
in the Drug Manufacturers industry
Industry Median: 3.54
vs ROCO:6620: 49.11
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Handa Pharmaceuticals 3-Year ROIIC % Related Terms
Handa Pharmaceuticals 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Handa Pharmaceuticals's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Handa Pharmaceuticals's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Handa Pharmaceuticals 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Handa Pharmaceuticals's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Handa Pharmaceuticals's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Handa Pharmaceuticals (ROCO:6620) has a 3-Year ROIIC % of 49.11 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Handa Pharmaceuticals and its competitors. This is near median its historical median of 51.77. According to the industry distribution chart, Handa Pharmaceuticals ranks #157 out of 944 companies in the Drug Manufacturers industry, placing it in the top 16.6%.
Is Handa Pharmaceuticals' 3-Year ROIIC % too high?
Handa Pharmaceuticals' current 3-Year ROIIC % of 49.11 is near median its 10-year median of 51.77. The Drug Manufacturers industry median 3-Year ROIIC % is 3.54. Handa Pharmaceuticals' value of 49.11 is 1287.3% above this industry median. Based on the distribution chart, Handa Pharmaceuticals ranks #157 out of 944 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Handa Pharmaceuticals has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Handa Pharmaceuticals' 3-Year ROIIC % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Handa Pharmaceuticals ranks #157 out of 944 companies for 3-Year ROIIC %. This places Handa Pharmaceuticals in the top 17% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.54. Handa Pharmaceuticals' value of 49.11 is 1287.3% above this benchmark. While the company's 10-year median is 51.77 vs. the industry median of 3.54, Handa Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.54, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Handa Pharmaceuticals's current 3-Year ROIIC % of 49.11 is 1287.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Handa Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Handa Pharmaceuticals's current 3-Year ROIIC % is 49.11, which is near median its own 10-year median of 51.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Handa Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Handa Pharmaceuticals (ROCO:6620) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$153.49, compared to a current price of NT$80.80 — trading 47.4% below its estimated fair value. The current 3-Year ROIIC % is 49.11, which is near median its 10-year median of 51.77 and 1287.3% above the Drug Manufacturers industry median of 3.54. Handa Pharmaceuticals' overall GF Score™ is 76/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Handa Pharmaceuticals (ROCO:6620), the current 3-Year ROIIC % is 49.11 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Handa Pharmaceuticals (ROCO:6620) Overvalued in 2026?
Based on GuruFocus' analysis, Handa Pharmaceuticals stock appears to be undervalued.
The current stock price of NT$80.80 is trading 47.4% below its estimated GF Value™ of NT$153.49.
GuruFocus considers Handa Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for ROCO:6620:
3-Year ROIIC %: 49.11 (near median its 10-year median of 51.77)
GF Value™: NT$153.49 vs. price of NT$80.80 (47.4% below fair value)
Industry Position: 1287.3% above the Drug Manufacturers median (#157 of 944)
No single metric tells the full story. See the ROCO:6620 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Handa Pharmaceuticals Inc is a Taiwan-based specialty pharmaceutical company. It is engaged in the development of niche drugs. The company focuses on the development of high-barrier/patentable niche products.
76GF Score
Get the complete analysis for ROCO:6620
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6620 has been successfully added to your 
